Modern Lipid Management: The Updated Medicine Cabinet - Clinical Spotlight Meeting on Demand-Novel and Emerging Therapies: Inclisiran

Novel and Emerging Therapies: Inclisiran

Video Transcription

Video Summary

The video is a presentation about a new therapy called inclisiran, which is a cholesterol-lowering agent in the siRNA class. The presenter explains that inclisiran works by inhibiting PCSK9, a protein that degrades LDL receptors, allowing LDL and the receptor to interact normally and reduce LDL levels. The presenter mentions that current PCSK9 inhibitors have low uptake due to cost and inconvenience. However, inclisiran offers a potential solution with twice-yearly injections providing durable and sustained LDL reduction of over 50%. The therapy has shown promising results in preclinical and clinical studies, and the presenter suggests that inclisiran could be an additional option for patients with atherosclerotic cardiovascular disease.

Keywords

inclisiran

cholesterol-lowering agent

siRNA class

PCSK9 inhibitor

LDL reduction